See more : Buffalo Coal Corp. (BUC.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Therma Bright Inc. (TBRIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Therma Bright Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Colas SA (RE.PA) Income Statement Analysis – Financial Results
- PsyBio Therapeutics Corp. (PSYB.V) Income Statement Analysis – Financial Results
- MDxHealth SA (0O8G.L) Income Statement Analysis – Financial Results
- Golden Ponder Holdings Limited (1783.HK) Income Statement Analysis – Financial Results
- HMT Limited (HMT.BO) Income Statement Analysis – Financial Results
Therma Bright Inc. (TBRIF)
About Therma Bright Inc.
Therma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.07K | 23.90K | 139.43K | 3.88K | 3.78K | 6.91K | 14.10K | 31.16K | 4.79K | 1.71K | 0.00 | 0.00 | 0.00 | 0.00 | 172.75K | 251.02K | 250.86K | 770.03K | 43.81K | 38.54K | 37.83K | 6.50K |
| Cost of Revenue | 614.00 | 0.00 | 75.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 439.00 | 0.00 | 0.00 | 0.00 | 0.00 | 141.00K | 372.71K | 121.96K | 281.02K | 27.43K | 24.08K | 23.72K | 0.00 |
| Gross Profit | 25.46K | 23.90K | 63.48K | 3.88K | 3.78K | 6.91K | 14.10K | 31.16K | 4.79K | 1.27K | 0.00 | 0.00 | 0.00 | 0.00 | 31.75K | -121.69K | 128.90K | 489.01K | 16.38K | 14.45K | 14.11K | 6.50K |
| Gross Profit Ratio | 97.64% | 100.00% | 45.53% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 74.31% | 0.00% | 0.00% | 0.00% | 0.00% | 18.38% | -48.48% | 51.38% | 63.50% | 37.38% | 37.50% | 37.30% | 100.00% |
| Research & Development | 9.69K | 446.58K | 805.54K | 1.37M | 13.08K | 60.67K | 92.49K | 97.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 570.00 | 9.05K | 58.65K | 0.00 | 0.00 |
| General & Administrative | 1.15M | 3.18M | 4.94M | 7.17M | 597.83K | 346.27K | 1.16M | 898.70K | 210.34K | 351.86K | 440.91K | 317.77K | 0.00 | 0.00 | 756.94K | 0.00 | 0.00 | 0.00 | 0.00 | 704.05K | 706.22K | 26.73K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 68.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 343.04K | 0.00 | 0.00 | 0.00 | 0.00 | 2.12K | 23.22K | 115.00 |
| SG&A | 1.15M | 3.18M | 4.94M | 7.17M | 597.83K | 346.27K | 1.16M | 898.70K | 210.34K | 351.86K | 440.91K | 317.77K | 262.41K | 193.63K | 1.10M | 1.30M | 1.22M | 1.96M | 1.15M | 706.17K | 729.44K | 26.84K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.15M | 1.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.16M | 3.63M | 5.90M | 8.60M | 613.89K | 409.73K | 1.25M | 996.51K | 210.34K | 351.86K | 440.91K | 317.77K | 262.41K | 193.63K | 1.11M | 1.32M | 1.31M | 2.10M | 1.18M | 713.41K | 931.71K | 28.10K |
| Cost & Expenses | 1.16M | 3.63M | 5.98M | 8.60M | 613.89K | 409.73K | 1.25M | 996.51K | 210.34K | 352.30K | 440.91K | 317.77K | 262.41K | 193.63K | 1.25M | 1.70M | 1.43M | 2.38M | 1.21M | 737.49K | 955.43K | 28.10K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.06K | 0.00 | 0.00 |
| Interest Expense | 8.60K | 13.44K | 1.38K | 0.00 | 17.40K | 18.91K | 8.74K | 0.00 | 0.00 | 3.90K | 643.97K | 550.99K | 473.02K | 423.68K | 312.72K | 267.74K | 0.00 | 0.00 | 0.00 | 1.27K | 0.00 | 0.00 |
| Depreciation & Amortization | 99.51K | 75.38K | 53.85K | 57.98K | 2.98K | 2.79K | 76.00 | 247.00 | 22.82K | 3.90K | 1.80M | 2.30M | 473.02K | 423.68K | 8.89K | 20.34K | 97.21K | 136.62K | 35.73K | 21.00K | 202.27K | 163.63K |
| EBITDA | -2.34M | -3.68M | -5.73M | -8.55M | -606.31K | -400.24K | -1.24M | -965.10K | -205.55K | -350.59K | 710.24K | 1.43M | -262.41K | -193.63K | -1.07M | -1.82M | -1.09M | -1.47M | -1.13M | -1.35M | -466.92K | -715.33K |
| EBITDA Ratio | -8,988.07% | -15,393.76% | -4,077.18% | -219,824.44% | -16,048.82% | -5,793.37% | -8,768.46% | -3,096.93% | -4,288.52% | -20,514.16% | 0.00% | 0.00% | 0.00% | 0.00% | -618.36% | -567.40% | -433.19% | -190.85% | -2,582.01% | -1,759.32% | -1,890.80% | 2,184.40% |
| Operating Income | -1.14M | -3.60M | -5.68M | -8.54M | -607.13K | -400.03K | -1.24M | -965.34K | -205.55K | -354.49K | -1.08M | -868.76K | -735.43K | -617.31K | -1.09M | -1.44M | -1.18M | -1.61M | -1.17M | -698.95K | -917.60K | -21.60K |
| Operating Income Ratio | -4,355.04% | -15,076.51% | -4,077.18% | -219,824.44% | -16,048.82% | -5,793.37% | -8,769.00% | -3,097.72% | -4,288.52% | -20,742.36% | 0.00% | 0.00% | 0.00% | 0.00% | -633.18% | -575.50% | -471.94% | -208.59% | -2,663.56% | -1,813.82% | -2,425.45% | -332.17% |
| Total Other Income/Expenses | -1.32M | -164.64K | -196.39K | -74.54K | -19.56K | -21.90K | -8.81K | -247.00 | -472.00 | -1.88K | 1.15M | 1.73M | -41.06K | 0.00 | -420.04K | -390.97K | -228.63K | -95.70K | 17.40K | -589.48K | 3.76K | -42.30K |
| Income Before Tax | -2.45M | -3.77M | -5.88M | -8.61M | -626.68K | -421.93K | -1.24M | -965.59K | -206.02K | -356.37K | 68.21K | 860.04K | -735.43K | -617.31K | -1.51M | -1.84M | -1.41M | -1.70M | -1.15M | -1.96M | -959.90K | -21.65K |
| Income Before Tax Ratio | -9,402.79% | -15,765.40% | -4,218.03% | -221,744.06% | -16,565.74% | -6,110.51% | -8,769.54% | -3,098.51% | -4,298.37% | -20,852.60% | 0.00% | 0.00% | 0.00% | 0.00% | -876.33% | -731.25% | -563.07% | -221.02% | -2,623.86% | -5,079.90% | -2,537.27% | -332.93% |
| Income Tax Expense | 0.00 | 0.00 | 1.38K | -178.58K | 17.40K | 18.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 312.72K | 267.74K | 195.65K | 133.18K | 20.67K | 361.30K | -295.99K | -9.50K |
| Net Income | -2.45M | -3.77M | -5.88M | -8.61M | -626.68K | -421.93K | -1.24M | -965.59K | -206.02K | -356.37K | 68.21K | 860.04K | -735.43K | -617.31K | -1.51M | -2.10M | -1.61M | -1.84M | -1.15M | -2.32M | -663.91K | -12.15K |
| Net Income Ratio | -9,402.79% | -15,765.40% | -4,218.03% | -221,744.06% | -16,565.74% | -6,110.51% | -8,769.54% | -3,098.51% | -4,298.37% | -20,852.60% | 0.00% | 0.00% | 0.00% | 0.00% | -876.33% | -837.92% | -641.07% | -238.31% | -2,623.86% | -6,017.49% | -1,754.88% | -186.82% |
| EPS | -0.01 | -0.02 | -0.03 | -0.04 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | 0.01 | 0.01 | -0.01 | -0.01 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.06 | -0.02 | 0.00 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.04 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | 0.01 | 0.01 | -0.01 | -0.01 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.06 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 315.92M | 242.84M | 228.45M | 199.96M | 163.80M | 163.27M | 148.52M | 116.63M | 110.35M | 88.46M | 78.09M | 69.12M | 66.78M | 66.78M | 55.93M | 52.28M | 49.17M | 44.68M | 40.80M | 39.76M | 32.58M | 20.05M |
| Weighted Avg Shares Out (Dil) | 315.92M | 242.84M | 228.45M | 199.96M | 163.80M | 163.27M | 148.52M | 116.63M | 110.35M | 88.46M | 78.09M | 69.12M | 66.78M | 66.78M | 55.93M | 52.28M | 49.17M | 44.68M | 40.80M | 39.76M | 32.58M | 20.05M |
Therma Bright Engages Independent Trading Group as Market Maker
Toronto, Ontario--(Newsfile Corp. - July 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that,...
Therma Bright Q2, 2024 Market Update On Business
Medical Device Developer & Investor Taps 4 Markets With Growth Projections of USD $39.1B by 2030 Toronto, Ontario--(Newsfile Corp. - July 3, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner...
Therma Bright Closes Second & Final Tranche of Fully Subscribed Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce...
Therma Bright Completes Debt Settlements
Toronto, Ontario--(Newsfile Corp. - June 19, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that further to...
Therma Bright Closes $854,500 First Tranche of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - June 10, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce...
Therma Bright Announces up to $1,000,000 Unit Offering
Toronto, Ontario--(Newsfile Corp. - May 22, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announces that it proposes to undertake a...
Therma Bright Announces Strategic Review & Update on Investment in Inretio
Toronto, Ontario--(Newsfile Corp. - March 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced that its Board of Directors ("the...
Therma Bright's Venowave Accepted for Review By Center for Medicare & Medicaid Services for Permanent CPT and HCPCS codes
Company To Resume Trading on Toronto Stock Exchange Venture (TSXV) on February 7, 2024 Toronto, Ontario--(Newsfile Corp. - February 6, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of...
Therma Bright Provides Update on Cease Trade Order
Toronto, Ontario--(Newsfile Corp. - December 5, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announces that a cease trade order has...
Therma Bright Prepares FDA 513(g) Review Document for its AI-Driven Digital Cough Analyzer (DCA)
Company's DCA Solution Offers Robust Set of User and Medical Practitioner Features via an Android & iOS Mobile App and a Clinician Dashboard For Monitoring Patient's Cough Toronto, Ontario--(Newsfile Corp. - November 29, 2023) - Therma Bright Inc. (TSXV: THRM)...
Source: https://incomestatements.info
Category: Stock Reports